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for MM patients using non–melphalan-based conditioning regi-
mens. Patients were enrolled in the study after exhibiting response
to induction therapy and meeting eligibility criteria. The treatment
plan was designed to harvest a dose of 10  106 peripheral blood
CD34 cells/kg for the planned 2 transplants; however, a second
ASCT would be pursued only in the event that CR/VGPR was not
achieved after the ﬁrst ASCT. The conditioning regimen for the
ﬁrst ASCT included oral busulfan 0.75 mg/kg every 6 hours on
days 8 through 5, intravenous (IV) etoposide 10 mg/kg/day on
days 4 to 2, and cyclosphosphamide (CP) IV 60 mg/kg/day on
days on 3 and 2. The conditioning regimen for the second
ASCT included 96-hour (days 6 through 3) continuous infu-
sion of CP (6 g/m2) and total body irradiation of 600 cGy in 4
fractions (days 2 and 1), followed by reinfusion of stem cell
product. Forty evaluable patients have been analyzed. The median
patient age was 56 years, with a median time from diagnosis to ﬁrst
ASCT of 8.7 months. Thirteen patients met the criteria for high-
risk myeloma. After the ﬁrst ASCT, 15 patients had CR/VGPR, 11
proceeded to the second ASCT, 8 refused to proceed to the second
ASCT, and 6 others did not proceed for other reasons. All patients
were offered posttransplantation maintenance therapy and treated
with monthly bisphosphonate. There was no treatment-related
mortality. Overall, 2 of 29 patients who underwent single trans-
plantation died 17 and 15 months after the transplantation second-
ary to disease progression (DP) or pneumonia. Three out of 11
patients who underwent tandem transplantations died, 2 of DP at
15 and 26 months after the second transplantation, and 1 patient
with a history of gastric bypass died of cryptogenic cirrhosis/liver
failure at 7 months. The median time between the two ASCTs was
107 days. Improvement in response category occurred in 34% after
the ﬁrst ASCT and in a total of 55% after the second ASCT. The
overall CR/VGPR rate was 20% before ASCT, 52% after single
transplantation, and 64% after double transplantation. At a median
follow-up of 15 months from the last ASCT, PFS was 14 months
after single transplantation (n  29) and 23 months after double
transplantation (n  11) (P  .46). The overall survival has not
been reached for both groups. The median PFS was 41 months for
all those with CR/VGPR, versus 26 months for all others (P 
.0146). In conclusion, non–melphalan-based conditioning regi-
mens seem to be effective and safe.
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CD34CD38 AND CD34HLADR CONTENTS IN BMSC GRAFTS
CORRELATE WITH SHORT-TERM ENGRAFTMENT BUT HAVE NO INFLU-
ENCE ON LONG-TERM HEMATOPOIETIC RECOVERY IN PATIENTS WHO
RECEIVED AUTOLOGOUS BONE MARROW TRANSPLANTATION
Zubair, A.C.1, Kao, G.2, Ritz, J.2 1Mayo Clinic, Jacksonville, FL;
2Dana Farber Cancer Institute, Boston, MA.
Previous animal and human studies have demonstrated that the
number of CD34 subsets such as CD34CD38 and
CD34HLADR subsets in stem cell grafts is signiﬁcantly
associated with the speed of short-term hematopoietic reconstruc-
tion (SHR). The aim of this study was to determine whether these
CD34 subsets predict long-term hematopoietic reconstitution
(LHR) in recipients of autologous bone marrow transplantation
(ABMT).
We have examined 53 lymphoma patients who received ABMTs
to determine if total mononuclear cell dose, CFU-GM, CD34
cell dose and CD34 cell subsets (CD34CD38 and
CD34HLADR) correlate with both SHR and LHR. Time to
neutrophil engraftment (TNE) and time to platelet engraftment
(TPE) were used to measure SHR, and platelet count was used as
an indicator of LHR at day 100 and 1 year post-ABMT. A total of
42 and 38 patients were analyzed at day 100 and 1 year post-
transplant, respectively. Patients were excluded either because they
were deceased or there was lack of follow-up data. Using a univar-
iate unadjusted logistic regression analysis, all of the predictor
variables were signiﬁcantly associated with SHR. However, at day
100, only CFU-GM and CD34 cell dose signiﬁcantly predicted
LHR. In addition, at 1 year post-ABMT, only CD34 cell dose
predicted LHR. CD34 cell dose maintained its signiﬁcance in
multivariate analysis adjusting for age, sex, and disease. None of
the CD34 cell subsets predicted LHR.
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ELEVATED MEAN CORPUSCULAR VOLUME (MCV) FOLLOWING AUTOL-
OGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: INCIDENCE
AND SIGNIFICANCE
Hamadani, M.H.1, Kamble, R.1,2, Sethi, S.1,2, Kharfan-Dabaja, M.1,2,
Kern, W.3, Ozer, H.1,2, Selby, G.B.1,2 1Department of Internal Med-
icine, Oklahoma University Health Sciences Center, Oklahoma City,
OK; 2Section of Hematology & Oncology, Oklahoma City, OK; 3Depart-
ment of Pathology, Oklahoma University Health Sciences Center, Okla-
homa City, OK.
Background: A relationship between macrocytosis and the risk
of secondary leukemia has been suggested in long-term cancer
survivors after chemotherapy. The incidence and signiﬁcance of
MCV elevation after high-dose chemotherapy and autologous he-
matopoietic stem cell transplantation (ASCT) is unknown. Meth-
ods: A retrospective analysis of 130 consecutive patients who
underwent ASCT between January 1999 and December 2003 was
performed. Complete blood count proﬁle was analyzed at trans-
plantation and then at 6 months, 1 year, and yearly after transplan-
tation. Patients with relapse of disease within 6 months of trans-
plantation were excluded. Sixty-three of 130 (48%) patients were
eligible for the study. Patient characteristics and time to achieve
long-term hematologic recovery (hemoglobin 12 g/dL, WBC
4000/mm3, platelets  150,000/mm3) were analyzed. When avail-
able, history of alcohol abuse, abnormal liver function, thyroid
function, vitamin B12, and folate deﬁciency were recorded. Re-
sults: At median follow-up of 22 months (range, 6–58 months), 33
of 63 (52.8%) patients displayed elevated MCV 6 months post-
transplantation. The median patients age was 12 years (range, 1–76
years). Four patients underwent double transplantation. Median
time to engraftment for neutrophils and platelets was 12 and 19
days, respectively. The median time to trilineage hematologic
normalcy was 289 days; 27 of 33 (81%) patients had suboptimal
long-term hematopoietic recovery at 6 months (WBC, 5 months;
hemoglobin, 14 months; platelets, 22 months).
At 6 months posttransplantation, 15 of 43 (35%) adult patients
displayed elevated MCV (normal, 81–99 ﬂ); the mean pretrans-
plantation MCV of 97.5 ﬂ increased to 102.7 ﬂ (P  .004). Of the
20 pediatric patients, 18 (91%) displayed elevated MCV at 6
months posttransplantation; mean pretransplantation MCV of 90.8
ﬂ increased to 94.1 ﬂ (P  .001). Persistent MCV elevation was
observed in 17 of 26 patients (65%) at 1 years posttransplantation
and in 7 of 14 patients (50%) at 2 years posttransplantation.
Pretransplantation red cell distribution width (RDW) was higher
pretransplantation (63%) than at 6 months posttransplantation
(45%). Further investigations of MCV elevation available in 10
patients were negative. No patients developed MDS or leukemia.
Conclusion: MCV elevation after high-dose chemotherapy and
ASCT is frequent, with an incidence of 52.8%. Macrocytosis
occurred unrelated to anemia; routine workup of macrocytosis is
unnecessary. Longer follow-up is needed to determine its signiﬁ-
cance, if any.
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MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL
STEM CELL TRANSPLANTATION WITHOUT THE USE OF BLOOD PROD-
UCTS
Jamal, F., Lim, S.W., Vescio, R., Pepkowitz, S., Van Strien, P.,
Hoshal, K., Lill, M.C. Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Refusal of blood products poses a treatment chal-
lenge for Jehovah’s Witness patients whose malignant diseases
require high dose chemotherapy. We report our ﬁndings from a
series of Jehovah’s Witness patients who were enrolled in our
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transfusion-free autologous stem cell transplantation protocol.
Methods: Seven patients were enrolled with malignancies that
would be treated with high dose chemotherapy. Four patients had
lymphoma, 1 patient had Ph acute lymphocytic leukemia, 1
patient had progressive CNS germinoma, and 1 patient had mul-
tiple myeloma. All patients underwent autologous stem cell trans-
plantation when in partial or complete remission. Patients entered
the study 8 weeks before anticipated stem cell transplantation and
received a regimen of recombinant erythropoietin, 40,000 U once
or twice weekly with the aim of achieving a hemoglobin level of 15
g/dL. G-CSF 10 g/kg was given for 5 days for stem cell mobili-
zation. High-dose therapy was disease-speciﬁc. Results: All pa-
tients suffered signiﬁcant pancytopenia, with no major side effects
in 6 of the 7 patients enrolled. One patient with progressive CNS
germinoma died from cerebral hemorrhage shortly after stem cell
infusion, but her platelet count was 31  109/L and hemoglobin
level was 16.4 g/dL before death. It is unlikely that her intracranial
hemorrhage was due purely to thrombocytopenia, but it may have
reﬂected tumor necrosis secondary to chemotherapy. The other
patients all remain in complete remission to date. They are now
45, 36, 24, 9, 5, and 1 months status posttransplanta-
tion. Conclusion: Autologous stem cell transplantation is a feasi-
ble treatment option for Jehovah’s Witness patients. Refusal of
blood product support should not be considered an absolute con-
traindication for high-dose chemotherapy and autologous stem cell
transplantation.
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HPC IN PERIPHERAL BLOOD PREDICTS CFU ACTIVITY AND TIME TO
ENGRAFTMENT IN AUTOLOGOUS APHERESIS PBSC PRODUCTS AS EF-
FECTIVELY AS CD34 CELL COUNT
Creer, M.H.1, Regan, D.M.2, Saridey, S.K.3, Oliver, D.A.4 1Depart-
ment of Pathology, Saint Louis University, Saint Louis, MO; 2Saint
Louis Cord Blood Bank, Saint Louis, MO; 3Department of Internal
Medicine, Saint Louis University,Saint Louis, MO; 4Saint Louis Uni-
versity Cancer Center, Saint Louis, MO.
In autologous PBSC products collected after growth factor mo-
bilization, previous studies have shown that measurements of HPC
correlate with CD34 cell count in peripheral blood (PB) before
apheresis collection. Because CFU activity in the ﬁnal product is
expected to be a standard measure of HSC/HPC content, we
compared the HPC and CD34 counts in PB before collection with
CFU in the ﬁnal product, to determine the utility of preapheresis
HPC in identifying patients likely to produce a suitable product.
By measuring CD34 and total MNC cell content in PB before
collection, midway through collection, and in the ﬁnal product, we
found that the ratio of CD34/MNC remained constant. This
demonstrates that recovery of progenitor cells and MNC is iden-
tical throughout collection and processing. This observation allows
calculation of expected CFU content in the ﬁnal product based on
preapheresis HPC and CD34 measurements. Using the observed
product ratio of CFU/CD34 (0.192  0.102) and the expected
product ratio of CFU/HPC (0.113  0.060) (n  25 for both
values), we compared the predicted product CFU content based on
observed HPC and CD34 cell count in preapheresis peripheral
blood with the actual CFU content recovered in the ﬁnal product.
Results: Autologous products (n  12) from 10 patients were
compared between CFU (106) predicted by peripheral blood HPC
(median, 21; range, 0–416) and CD34 (median, 11; range, 0–165)
with actual CFU (median, 23; range, 4–131) obtained on the ﬁnal
product (P .08; Freidman test). A strong linear association was
noted between actual CFU and preaphersis HPC (Spearman rank
correlation  0.84). Conclusion: This pilot study suggests that
HPC in peripheral blood predicts CFU content as effectively as
CD34. For 75% of the samples, the observed CFU and the CFU
predicted by HPC was higher than the CFU predicted by CD34,
possibly indicating a CD34 fraction that is capable of colony
formation and that can be measured by the HPC parameter.
GRAFT PROCESSING
201
EXPERIENCES OF PERIPHERAL BLOOD STEM CELLS COLLECTION
FROM RADIAL ARTERY FOR UNRELATED DONOR TRANSPLANTATION
Chen, R.L., Ro, Y.C., Yeh, S.Y., Lin, D.Y., Hsu, W.L. Buddhist Tzu
Chi Stem Cells Center, Hualien, Taiwan.
Many donors with inadequate peripheral venous access were
encountered in our center. Central venous access was an alternative
method of peripheral blood stem cell (PBSC) collection but posed
signiﬁcant risks to donors. Although the frequency of progenitor
cells in the radial arteries was reduced in comparison to that in the
central veins, probably associated with pulmonary PBSC trapping,
the impact on clinical PBSC transplantation may be negligible.
The experiences of 27 PBSC unrelated donors who had inadequate
peripheral venous access and were collected from radial arterial
line are reported. There were 18 males and 9 females, ranging in
age from 23 to 52 years (median, 29 years). The body weight of
donors ranged from 50 to 106.5 kg (median, 63 kg); that of
recipients, from 20 to 103 kg (median, 62 kg). All donors were
treated with 4–5 days of ﬁlgramstim at an approximate dose of 10
mg/kg/day and underwent 1–2 days of apheresis with a continuous-
ﬂow blood cell separator. Preapheresis white cell and platelet
counts were 37.5  8.9  109/mL and 196  36  109/mL,
respectively. Calcium gluconate replacement was administered
while the patients complained of numbness. A total of 19.2  6.6
L of blood was processed per donor. Collection took 5.9  2.1
hours per donor. A total of 501  155  108 nucleated cells and
347  188  106 CD34 cells per donor were collected. These
yielded 8.7  3.6  108 total nucleated cells and 6.0  3.5  106
CD34 cells/kg of the recipient weight. None of PBSC donors
was noted to have laboratory hypocalcemia. The platelet count
ranged from 95 to 179  109/mL (median, 132) immediately
postapheresis, which corresponded to a decrease of 55  27 
109/mL. Two donors still experienced anorexia, headache, malaise,
or myalgia 1 week postapheresis, but none did 1 month posta-
pheresis. The white cell count, lymphocyte count, and platelet
count 1 month postapheresis was 5.5 1.5 109/mL, 1.7 0.4
109/mL, and 227  45  109/mL, respectively. Engraftment rate
of recipients was 100% after exclusion of 2 early deaths (1 before
and another 6 days after PBSC infusion). PBSC collection from a
radial arterial line might be acceptable for unrelated donor trans-
plantation when the donor has inadequate peripheral venous ac-
cess.
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EFFECT OF THE NUMBER OF DAYS REQUIRED FOR COLLECTION OF
ALLOGENEIC PERIPHERAL BLOOD STEM CELLS ON ENGRAFTMENT
Devetten, M.P., Lynch, J.C., Petersen, K.A., Kessinger, A. University of
Nebraska Medical Center, Omaha, NE.
The use of peripheral blood stem cells (PBSCs) for allogeneic
transplantation continues to increase. The relationship between
ease of mobilization of PBSC and engraftment after transplanta-
tion has not been extensively studied. We retrospectively analyzed
the relationship between days of collection by apheresis (catego-
rized as 1, 2, and  2) and engraftment in 109 matched sibling
donor/recipient pairs who underwent collection between March
1995 and November 2003. All donors recieved G-CSF at 10 g/kg
for 4 days, with collection started on the ﬁfth day. Daily G-CSF
administration and collection were continued until a minimum of
3  106 CD34 cells/kg per recipient had been collected. Cells
were frozen and stored in DMSO until infusion. All grafts were
unmanipulated, and all recipients received G-CSF posttransplan-
tation. Fifty-one donors (47%) required 1 day to collect an ade-
quate graft, 52 donors (48%) required 2 days, and 6 donors (6%)
required  2 days. Females were more likely to require  1 day of
collection (P  .01). Donors who required  2 days for collection
were older than donors who required only 1 or 2 days (P  .015).
There was no association between days required for collection and
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